Le et al. [57] assessed the value of a granulocyte macrophage colony-stimulating factor (GM-CSF) transduced allogeneic pancreatic cancer cell line-based vaccine (GVAX) added to anti-CTLA-4 in gemcitabine pre-treated advanced PDAC patients. The gene discussed is CSF2; the disease is pancreatic neoplasm.